Researchers discover master regulator that drives majority of lymphoma
A soon-to-be-tested class of drug inhibitors were predicted to help a limited number of patients with B-cell lymphomas with mutations affecting the EZH2 protein. However, a research team, led by investigators at Weill Cornell ...
Cancer
May 13, 2013 |
5 / 5 (3) |
0
|
Scheduled imaging studies provide little help detecting relapse of aggressive lymphoma
Imaging scans following treatment for diffuse large B-cell lymphoma do little to help detect a relapse, a Mayo Clinic study has found. The overwhelming majority of patients with this aggressive lymphoma already have symptoms, ...
Cancer
May 16, 2013 |
not rated yet |
0
Searching for therapeutic synergy in primary effusion lymphoma
Primary effusion lymphoma (PEL) is a rare, fatal form of aggressive B-cell lymphoma caused by Kaposi's sarcoma-associated herpesvirus (KSHV). The disease most commonly occurs in immunocompromised patients, such as those with ...
Cancer
May 01, 2013 |
not rated yet |
0
